Pharming Group Ownership
| PHAR Stock | USD 7.65 0.12 1.59% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 67.8 M | Current Value 51.7 M | Avarage Shares Outstanding 51.6 M | Quarterly Volatility 83.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Pharming |
Pharming Stock Ownership Analysis
The book value of the company was at this time reported as 0.44. The company recorded a loss per share of 0.27. Pharming Group NV had not issued any dividends in recent years. Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Pharming Group operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 277 people. To find out more about Pharming Group NV contact MD MBA at 31 71 524 7400 or learn more at https://www.pharming.com.Besides selling stocks to institutional investors, Pharming Group also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pharming Group's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pharming Group's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pharming Group Quarterly Liabilities And Stockholders Equity |
|
Pharming Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pharming Group is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pharming Group NV backward and forwards among themselves. Pharming Group's institutional investor refers to the entity that pools money to purchase Pharming Group's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Silverberg Bernstein Capital Management Llc | 2024-09-30 | 41.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 5.6 K | Ubs Group Ag | 2024-06-30 | 789 | Advisor Group Holdings, Inc. | 2024-06-30 | 568 |
Pharming Group NV Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pharming Group insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pharming Group's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pharming Group insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Camden Partners Strategic Fund Ii A Lp over three months ago Acquisition by Camden Partners Strategic Fund Ii A Lp of 5000 shares of Pharming Group at 0.68 subject to Rule 16b-3 |
Pharming Group Outstanding Bonds
Pharming Group issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pharming Group NV uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pharming bonds can be classified according to their maturity, which is the date when Pharming Group NV has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PHARMACIA P 66 Corp BondUS71713UAW27 | View | |
| PHARMACIA P 675 Corp BondUS71713UAT97 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Pharming Group Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
6K | 24th of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 4th of April 2024 Other Reports | ViewVerify |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.